Show simple item record

dc.contributor.authorAlbasri, Ali
dc.contributor.authorHattle, Miriam
dc.contributor.authorKoshiaris, Constantinos
dc.contributor.authorDunnigan, Anna
dc.contributor.authorPaxton, Ben
dc.contributor.authorFox, Sarah
dc.contributor.authorSmith, Margaret
dc.contributor.authorArcher, Lucinda
dc.contributor.authorLevis, Brooke
dc.contributor.authorPayne, Rupert
dc.contributor.authorRiley, Richard
dc.contributor.authorRoberts, Nia
dc.contributor.authorSnell, Kym
dc.contributor.authorLay-Flurrie, Sarah
dc.contributor.authorUsher-Smith, Juliet
dc.contributor.authorStevens, Richard
dc.contributor.authorHobbs, Richard
dc.contributor.authorMcManus, Richard
dc.contributor.authorSheppard, James
dc.date.accessioned2021-01-13T00:30:43Z
dc.date.available2021-01-13T00:30:43Z
dc.date.issued2021-02-10
dc.identifier.issn0959-535X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/316113
dc.description.abstractObjectives: There are many meta-analyses of randomised controlled trials (RCTs) which examine the efficacy of antihypertensive treatment, but few have studied the potential harms. The aim of this study was to examine the association between antihypertensive treatment and specific adverse events. Design: Systematic review and meta-analysis of RCTs. Eligibility criteria: Articles were eligible if they examined adults taking antihypertensive treatment compared to placebo/no treatment, more treatment vs. less treatment, or higher blood pressure targets vs. lower targets. To avoid small early phase trials, studies were required to have at least 650 patient-years of follow-up. Information sources: Searches were conducted in Embase, MEDLINE, Cochrane CENTRAL and the Science Citation Index databases from inception until 14/04/2020. Main outcome measures: The primary outcome was falls at any time point during trial follow-up. Secondary outcomes were acute kidney injury (AKI), fractures, gout, hyperkalaemia, hypokalaemia, hypotension and syncope. Additional outcomes related to death and major cardiovascular events were extracted. Risk of bias was assessed using the Cochrane risk of bias tool, and random-effects meta-analysis was used to pool rate ratios, odds ratios and hazard ratios across studies allowing for between-study heterogeneity (tau2). Results: A total of 15,023 articles were screened for inclusion and 58 RCTs were identified, including 280,638 participants, followed-up for a median of 3 years (IQR 2-4). The majority of trials (69%) had a low risk of bias. Across seven trials, there was no evidence of an association between antihypertensive treatment and falls (summary risk ratio [RR] 1.05, 95%CI 0.89-1.24, tau2=0.009). Antihypertensives were associated with an increased risk of AKI (RR 1.18, 95%CI 1.01-1.39, tau2=0.037, n=15), hyperkalaemia (RR 1.89, 95%CI 1.56-2.30, tau2=0.122, n=26), hypotension (RR 1.97, 95%CI 1.67-2.32, tau2=0.132, n=35) and syncope (RR 1.28, 95%CI 1.03-1.59, tau2=0.050, n=16). The heterogeneity between studies assessing AKI and hyperkalaemia events was reduced when focussing on medications affecting the renin angiotensin-aldosterone system. Results were robust to sensitivity analyses focusing on adverse events leading to withdrawal from each trial. Antihypertensive therapy was associated with a reduced risk of all-cause mortality, cardiovascular death and stroke, but not myocardial infarction. Conclusions: This meta-analysis does not suggest that antihypertensive treatment is associated with falls, but provides evidence of an association with other mild/severe adverse events, some of which were drug class specific. These data may be used to inform shared decision-making between physicians and patients regarding antihypertensive initiation and continuation, especially in patients at high risk of harm. Registration: PROSPERO CRD42018116860
dc.publisherBMJ Publishing Group
dc.rightsAttribution 4.0 International (CC BY)
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleAssociation between antihypertensive treatment and adverse events: systematic review and meta-analysis
dc.typeArticle
prism.publicationNameBMJ: British Medical Journal
dc.identifier.doi10.17863/CAM.63221
dcterms.dateAccepted2021-01-11
rioxxterms.versionofrecord10.1136/bmj.n189
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-01-11
dc.contributor.orcidUsher-Smith, Juliet [0000-0002-8501-2531]
dc.identifier.eissn1756-1833
rioxxterms.typeJournal Article/Review
pubs.funder-project-idCancer Research UK (21464)
cam.issuedOnline2021-02-10
cam.orpheus.successMon Jun 07 07:33:04 BST 2021 - The item has an open VoR version.
cam.orpheus.counter19
rioxxterms.freetoread.startdate2100-01-01


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY)
Except where otherwise noted, this item's licence is described as Attribution 4.0 International (CC BY)